{"id":"W3217436200","doi":"10.1182/blood-2021-150519","title":"Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary; McGill University Health Centre","funders":"","keywords":"Medicine; Multiple myeloma; Cytokine release syndrome; Lenalidomide; Adverse effect; Common Terminology Criteria for Adverse Events; Neutropenia; Internal medicine; Pomalidomide; Oncology; Febrile neutropenia; Toxicity; Pharmacology; Gastroenterology; Immunotherapy; Cancer; Chimeric antigen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000174774,0.0004043127,0.0005353927,0.0002010567,0.0003221769,0.0001022786,0.000166449,0.0002076494,0.000204524],"category_scores_gemma":[0.001220318,0.0003072213,0.0001545295,0.0004811002,0.00007006651,0.0002423874,0.00008183681,0.0004083525,0.00007867114],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001110775,"about_ca_system_score_gemma":0.0004115237,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002244423,"about_ca_topic_score_gemma":0.0002095327,"domain_scores_codex":[0.9967734,0.000191747,0.0005799361,0.0009656354,0.0007951701,0.0006941513],"domain_scores_gemma":[0.9972405,0.0006167919,0.0002388217,0.0008552275,0.0006570287,0.0003915685],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.1403281,0.04575989,0.3199775,0.001250787,0.00463257,0.01084349,0.003851858,0.0000287473,0.4085243,0.00003001074,0.01779716,0.04697561],"study_design_scores_gemma":[0.1726496,0.003647199,0.6086013,0.0004903203,0.0006276345,0.0000366245,0.0005777596,0.001180408,0.2031126,0.00002476616,0.008330801,0.0007210064],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932094,0.00110987,0.0003070085,0.0003218751,0.0001707244,0.001951616,0.001867658,0.0001584509,0.0009034101],"genre_scores_gemma":[0.9621274,0.0002354204,0.02441044,0.0001135596,0.0001960486,0.0001752913,0.01073063,0.0001058429,0.00190533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2886238,"threshold_uncertainty_score":0.999938,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.016623479650107,"score_gpt":0.2455051673231636,"score_spread":0.2288816876730566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}